锥形束CT引导经动脉化疗栓塞治疗米兰标准内肝细胞癌的疗效与安全性:回顾性队列研究
该回顾性队列研究比较了锥形束CT(CBCT)引导与常规血管造影引导经动脉化疗栓塞(TACE)治疗米兰标准内肝细胞癌的疗效与安全性。CBCT-TACE组(55例)局部无进展生存期显著长于Angio-TACE组(58例),且栓塞后综合征发生率显著更低,但两组无进展生存期和总生存期无显著差异。
要点
- CBCT引导TACE可延长米兰标准内HCC的局部无进展生存期(中位未达到 vs 19.2个月,p=0.029)。
- CBCT引导与局部进展或死亡风险降低独立相关(校正HR 0.585,95%CI 0.344-0.995,p=0.048)。
- CBCT-TACE组栓塞后综合征发生率显著低于Angio-TACE组(p=0.002)。
核心结论
- CBCT引导TACE可改善米兰标准内肝细胞癌的局部肿瘤控制,并减少栓塞后综合征的发生。
研究设计与样本
- 回顾性队列研究,比较Angio-TACE组58例(2010年1月至2011年12月)与CBCT-TACE组55例(2013年1月至2014年12月)的疗效与安全性。
诊断标准与关键数值
- 局部无进展生存期:CBCT-TACE组中位未达到 vs Angio-TACE组19.2个月,Log-rank p=0.029。
- 多变量Cox回归:CBCT引导的局部进展或死亡校正HR 0.585(95%CI 0.344-0.995,p=0.048)。
- 3年无进展生存率:Angio-TACE组15.9% vs CBCT-TACE组26.8%(p=0.122)。
- 3年总生存率:Angio-TACE组85% vs CBCT-TACE组88.2%(p=0.761)。
- 栓塞后综合征发生率CBCT-TACE组显著低于Angio-TACE组(p=0.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To compare the therapeutic efficacy and safety of transarterial chemoembolisation (TACE) for hepatocellular carcinoma (HCC) within the Milan criteria with or without the use of cone-beam computed tomography (CBCT).
MATERIALS AND METHODS: Patients with HCC within the Milan criteria who underwent conventional angiography-guided TACE (Angio-TACE group: 58 patients from January 2010 to December 2011) were compared with those who underwent CBCT-guided TACE (CBCT-TACE group: 55 patients from January 2013 to December 2014). Local progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were compared. Adverse events after TACE were also investigated.
RESULTS: Baseline characteristics were balanced between the two groups. LPFS was significantly longer in the CBCT-TACE group than in the Angio-TACE group (median: not reached for 36 versus 19.2 months, respectively; Log-rank p=0.029). In multivariable Cox regression analysis, CBCT guidance had a significantly lower risk of local progression or death (adjusted hazard ratio: 0.585; 95% confidence interval, 0.344-0.995; p=0.048); however, there was no significant difference in PFS (3-year PFS: 15.9% versus 26.8%, respectively; p=0.122) or OS (3-year OS: 85% versus 88.2%, respectively; p=0.761) between the Angio-TACE and CBCT-TACE groups. Post-embolisation syndrome occurred significantly less frequently in the CBCT-TACE group (p=0.002).
CONCLUSION: CBCT-guided TACE could improve local tumour control for HCC within Milan criteria and showed fewer cases of post-embolisation syndrome.
引用
- Lee JH, Lee IJ, Kim HB, et al. Efficacy and safety of transarterial chemoembolisation with cone-beam CT in patients with hepatocellular carcinoma within the Milan criteria: a retrospective cohort study. Clin Radiol. 2019. PMID: 30837076. doi:10.1016/j.crad.2019.01.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。